Oncology institutions across the United States are implementing big change in the way nurses and physicians deliver care to patients with cancer. By highlighting quality care and smart spending, facilities are reimagining the way cancer is treated in America. New procedures, research, and technology have redefined the way cancer is treated, so a new system for delivery and reimbursement is vital to ensure that quality care can be delivered at a reasonable cost.
Oncology care is a complex, expensive, and often-fragmented area of medicine. To understand the potential need for a new payment model in oncology care, a thorough evaluation of all the data was important. By reviewing the oncology literature associated with costs and quality, we discovered that there were wide variations in the costs associated with the treatment of advanced cancers, but little variation in the outcomes of patients. We also identified gaps in patient care that we thought could be improved.
Every year, oncology research marches toward new, innovative treatments for patients with cancer. Cancer research is a cumulative process—building upon itself year after year—but, with time, major changes begin to make their way into practices across the country. Some of these advancements stand to change the face of cancer treatment for years to come. In a field of constant evolution, oncology nurses and their colleagues need to stay abreast of developments in science and technology as new knowledge is uncovered in the treatment of cancer.
The Institute for Safe Medication Practices (ISMP) has added five new best practices and revised two existing ones for safe medication administration in its recent release of the 2016-2017 Targeted Medication Safety Best Practices for Hospitals.
By 2035, it’s expected that 22 million new cancer cases will be diagnosed annually around the world. The global burden of cancer care and treatment is something that affects all nations and cultures. Through collaboration, understanding, and a dedication to forging new relationships, oncology professionals from around the world are coming together to fight for their patients and colleagues on February 4, 2017, for World Cancer Day.
After more than 40 years as an oncology educator, researcher, and nurse, ONS member Karen Meneses, PhD, RN, FAAN, has been named the University of Alabama at Birmingham’s (UAB’s) 2016 Distinguished Faculty Lecturer. This is the highest honor given at the university, and Meneses is only the second nurse from UAB’s school of nursing to ever receive the honor.
More than ever before, oncology nurses are required to provide multifaceted care when it comes to managing patients with cancer. As the population of patients with cancer continues to age and cancer becomes more of a chronic condition, oncology nurses are seeing more patients who exhibit comorbidities during their cancer journey.
Access devices have been used for decades to administer the complex treatments and supportive care that oncology nurses deliver daily to patients with cancer. As these devices and other products evolve, nurses need evidence-based methodologies for critiquing their safety and effectiveness.
The ONS clinical inbox frequently receives questions about whether nurses need to be “chemotherapy certified” to give specific chemotherapy and/or biotherapy agents.
One of the questions that ONS commonly receives in the clinical inbox is whether nurses who are pregnant, breastfeeding, or trying to conceive can safely administer or handle chemotherapy and other hazardous drugs.